<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624725</url>
  </required_header>
  <id_info>
    <org_study_id>2018-02-R</org_study_id>
    <nct_id>NCT03624725</nct_id>
  </id_info>
  <brief_title>A Clinical Study of the Effects of Modified BII+Braun on Quality of Life After for Distal Gastric Cancer</brief_title>
  <official_title>A Single-center, Randomized, Controlled Clinical Study of the Effects of Modified and Traditional BII+Braun Digestive Tract Reconstruction Methods on Quality of Life After Radical Gastrectomy for Distal Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xue Yingwei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Affiliated Hospital of Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the
      anastomotic site, and the jejunum of the output segment is extended to 30cm
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The T1-4a N0-3 M0 gastric adenocarcinoma patients were used to evaluate whether the quality
      of life after modified BII+Braun digestive tract reconstruction was superior to the
      traditional BII+Braun digestive tract reconstruction
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of quality of life</measure>
    <time_frame>The quality of life questionnaire was conducted at six months after surgery.</time_frame>
    <description>The GSRS scoring system was used to understand the functional status of the digestive tract and its impact on quality of life in postoperative patients .The GSRS scoring system was 0-3, with 0 being the mildest and 3 being the most severe</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">592</enrollment>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>modified BII+Braun</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>traditional BII+Braun</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>traditional BII+Braun digestive tract reconstruct</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>modified BII+Braun</intervention_name>
    <description>modified BII+Braun digestive tract reconstruction</description>
    <arm_group_label>modified BII+Braun</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18&lt;age&lt;75

          -  Gastric lesions were diagnosed as gastric adenocarcinoma by endoscopic biopsy

          -  The preoperative clinical stage is T1-4a,N0-3,M0(According to AJCC- 7th TNM tumor
             stage)

          -  It is expected that the results of R0 surgery can be obtained by performing distal
             gastrectomy and D2 lymph node dissection

          -  Preoperative ECOG performance status score 0/1

          -  Nutrition risk screening（NRS2002）

          -  Preoperative ASA score I-III

          -  Patient informed consent

        Exclusion Criteria:

          -  Pregnancy or breastfeeding women

          -  Severe mental illness

          -  History of upper abdominal surgery

          -  History of gastric surgery (including ESD/EMR for gastric cancer)

          -  3 years of history of other malignant diseases；

          -  Gastric cancer patients who have undergone neoadjuvant treatment or recommend
             neoadjuvant treatment

          -  A history of unstable angina or myocardial infarction within 6 months

          -  History of cerebral infarction or cerebral hemorrhage within 6 months

          -  There is a history of sustained systemic corticosteroid treatment within 1 month

          -  Needs simultaneous surgical treatment of other diseases；

          -  Gastric cancer complications (bleeding, perforation, obstruction) require emergency
             surgery

          -  Pulmonary function test FEV&lt;1 predicted value 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingwei Xue, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Director of Gastrointestinal surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Ma, doctor</last_name>
    <phone>+8613796655585</phone>
    <email>doctormayan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastrointestinal surgery of the affiated tumor hospital</name>
      <address>
        <city>Harbin</city>
        <state>Helongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Ma, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Third Affiliated Hospital of Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Xue Yingwei</investigator_full_name>
    <investigator_title>Director, Head of Gastrointestinal surgery, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

